High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)

被引：0
|
作者：
Samaniego, F. [1 ]
Pro, B. [1 ]
Nunez, R. [1 ]
McLaughlin, P. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Romaguera, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [11] Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy for indolent non-Hodgkin lymphoma
    Iino, Masaki
    Yamamoto, Takeo
    Sato, Tomoya
    Sakamoto, Yuma
    ANNALS OF ONCOLOGY, 2019, 30
  • [12] Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
    Sanchez Ruiz, Antonio C.
    de la Cruz-Merino, Luis
    Provencio Pulla, Mariano
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (03) : 78 - 90
  • [13] Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Gordon, LI
    Witzig, T
    Molina, A
    Czuczman, M
    Emmanouilides, C
    Joyce, R
    Vo, K
    Theuer, C
    Pohlman, B
    Bartlett, N
    Wiseman, G
    Darif, M
    White, C
    CLINICAL LYMPHOMA, 2004, 5 (02): : 98 - 101
  • [14] USE OF YTTRIUM-90-IBRITUMOMAB TIUXETAN IN NON-AGGRESSIVE B-CELL LYMPHOMA
    Paniagua Violeta, Gonzalez
    Jose Manuel, Gonzalez de la Pena Puerta
    Fernandez Blanca, De la Nogal
    Fernandez Gerardo, Hermida
    Martinez Begona, Miguel
    Garcia Magdalena, Gueemes
    ATENCION FARMACEUTICA, 2010, 12 (05): : 317 - 323
  • [15] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
  • [16] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [17] Induction of complere molecular response with yttrium-90 ibritumomab tiuxetan (zevalin®) in B cell non Hodgkin's lymphoma patients after the achievement of a complete clinical response with chemotherapy regimen
    Orciuolo, E.
    Buda, G.
    Galimberti, S.
    Cecconi, N.
    Boni, G.
    Petrini, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 63 - 63
  • [18] A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease
    Samaniego, Felipe
    Romaguera, Jorge E.
    Fowler, Nathan
    Fanale, Michelle A.
    Shah, Jatin J.
    McLaughlin, Peter
    Pro, Barbara
    Selvaraj, Vijairam
    Braun, Frank K.
    Mathur, Rohit
    Feng, Lei
    Neelapu, Sattva
    Kwak, Larry W.
    BLOOD, 2013, 122 (21)
  • [19] Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.
    Morschhauser, F
    Huglo, D
    Martinelli, G
    Paganelli, G
    Zinzani, PL
    Hadjiyiannakis, D
    Liberati, A
    Illidge, T
    Milpied, N
    Stein, H
    Kalmus, J
    Morel, P
    Reimann, U
    Marcus, R
    BLOOD, 2004, 104 (11) : 41A - 41A
  • [20] Response evaluation of yttrium-90 ibritumomab-tiuxetan (Zevalin®) with fluor-18 FluoroDeoxyGlucose (FDG-PET)
    Huglo, D.
    Morschhauser, F.
    Prangere, T.
    Raynaud, F.
    Steinling, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S188 - S188
12345